Flavin Financial Services Inc. Sells 1,005 Shares of Pfizer Inc. (NYSE:PFE)

Flavin Financial Services Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 27,180 shares of the biopharmaceutical company’s stock after selling 1,005 shares during the quarter. Flavin Financial Services Inc.’s holdings in Pfizer were worth $689,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. Impax Asset Management Group plc bought a new stake in shares of Pfizer in the fourth quarter worth $713,000. FourThought Financial Partners LLC bought a new stake in shares of Pfizer in the fourth quarter worth $841,000. Finally, Denali Advisors LLC grew its stake in shares of Pfizer by 12.8% in the fourth quarter. Denali Advisors LLC now owns 37,100 shares of the biopharmaceutical company’s stock worth $984,000 after purchasing an additional 4,200 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1%

NYSE:PFE opened at $24.29 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a 50-day moving average of $23.38 and a 200-day moving average of $24.87. The company has a market cap of $138.10 billion, a PE ratio of 17.60, a PEG ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. Pfizer’s payout ratio is 124.64%.

Analyst Ratings Changes

Several research firms recently issued reports on PFE. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.